Novartis/QLT Visudyne Medicare Coverage Expansion Awaits More Data
Executive Summary
The Centers for Medicare & Medicaid Services will ask for unpublished information from a peer-reviewed study of Novartis/QLT's Visudyne (verteporfin) for age-related macular degeneration before it expands coverage to off-label indications
You may also be interested in...
QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
Novartis, CMS Continue To Talk On Visudyne Macular Degeneration Coverage
Novartis and the Centers for Medicare & Medicaid Services will be meeting right up until the deadline for expanded coverage for Novartis/QLT's Visudyne